Berlin – In a significant move signaling continued consolidation within the digital health sector, Hims & Hers Health, Inc. Has announced a definitive agreement to acquire Eucalyptus, an Australian-based telehealth provider. The deal, valued at up to $1.15 billion, represents a major expansion for Hims & Hers beyond its North American base, positioning the company for growth in key international markets including Australia, Japan, the United Kingdom, Germany, and Canada. This acquisition underscores the increasing demand for accessible, personalized healthcare solutions and the growing investment in telehealth technologies globally.
The acquisition of Eucalyptus is strategically important for Hims & Hers, allowing it to tap into a rapidly expanding market and leverage Eucalyptus’s established presence and regulatory expertise. Founded in 2019, Eucalyptus has quickly grow a leading player in the Australian digital health landscape, operating a portfolio of consumer-focused brands and serving a substantial customer base. The deal is expected to close in mid-2026, subject to customary closing conditions, and will be financed through a combination of cash and potential stock options, minimizing immediate impact on Hims & Hers’ balance sheet.
Expanding Global Reach: Hims & Hers’ Strategic Acquisition
Hims & Hers Health, traded on the Latest York Stock Exchange under the ticker symbol HIMS, has been steadily expanding its portfolio of telehealth services, focusing on personalized care solutions for a range of conditions. The company’s core offerings include telehealth consultations, prescription medications, and over-the-counter products. The acquisition of Eucalyptus aligns with this strategy, providing Hims & Hers with a platform to extend its reach to new geographies and customer segments. According to the company, the move is driven by the recognition that “healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare,” as stated by founder and CEO Andrew Dudum. Hims & Hers Investor Relations
Eucalyptus: A Powerhouse in the Australian Telehealth Market
Eucalyptus has established itself as a dominant force in the Australian digital health market, operating a “house of brands” model similar to that of Hims & Hers. Its portfolio includes well-known brands such as Juniper, a weight-loss program, and Pilot, a men’s telehealth service. The company has served over 775,000 customers and currently boasts an annual revenue run-rate exceeding $450 million, demonstrating significant growth and market traction. CNBC. Eucalyptus’s success is also attributed to its commitment to clinical rigor, being the first Australian telehealth business to receive accreditation from the Australian Council on Healthcare Standards (ACHS).
This accreditation is particularly significant in a highly regulated market like Australia, demonstrating Eucalyptus’s adherence to stringent quality and safety standards. The company’s ability to navigate the Australian regulatory landscape will be a valuable asset for Hims & Hers as it expands its operations in the region. Eucalyptus has also reported triple-digit year-over-year growth in its annual revenue run-rate throughout 2025, further solidifying its position as a market leader.
Financial Details of the Acquisition
The total acquisition price of up to $1.15 billion will be paid in stages. Hims & Hers will initially pay approximately $240 million in cash upon closing, with the remaining amount consisting of guaranteed deferred payments over the following 18 months, plus potential earnout payments tied to specific financial targets through early 2029. The company has the flexibility to settle these deferred and earnout payments in either cash or stock, providing financial maneuverability. Hims & Hers intends to finance the initial cash outlay with existing cash reserves, minimizing the need for additional borrowing. Reuters
Leadership Transition and Future Integration
As part of the integration process, Tim Doyle, the current CEO and co-founder of Eucalyptus, will assume the role of Senior Vice President of International at Hims & Hers. In this capacity, he will oversee the combined company’s global business operations, leveraging his expertise and experience to drive international expansion. Doyle expressed his enthusiasm for the acquisition, stating that it will “accelerate the movement towards affordable healthcare for everyone.”
The acquisition comes at a complex time for Hims & Hers. The company is currently involved in a lawsuit with Danish drugmaker Novo Nordisk following a crackdown by the U.S. Food and Drug Administration (FDA) that forced the withdrawal of its $49 copy of Novo’s Wegovy weight-loss pill. This legal challenge adds another layer of complexity to the integration process, but Hims & Hers appears confident in its ability to navigate these challenges and capitalize on the opportunities presented by the Eucalyptus acquisition.
Key Takeaways
- Global Expansion: Hims & Hers significantly expands its international footprint into Australia, Japan, the UK, Germany, and Canada.
- Strategic Acquisition: Eucalyptus brings a strong brand portfolio, a large customer base, and valuable regulatory expertise.
- Financial Flexibility: The acquisition is structured to minimize financial risk for Hims & Hers, with a phased payment plan.
- Leadership Integration: Eucalyptus CEO Tim Doyle will play a key role in driving international growth within Hims & Hers.
The closing of the acquisition is anticipated in mid-2026. Investors and industry observers will be closely watching the integration process and the impact of the acquisition on Hims & Hers’ financial performance and market position. The company’s next earnings call, scheduled for [date to be confirmed], will likely provide further insights into its integration plans and outlook for the future.
What are your thoughts on this acquisition? Share your comments below, and let us understand how you think this will impact the future of telehealth!
Keep reading